newsfilter
← Latest News
GlobeNewswire·

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE:MAIA)